Interplay with domestic “Big Three” business tax relief provisions
The combined effect of the OBBBA’s international tax reforms may vary depending on a company’s specific circumstances, and the actual ETRs for multinationals will be difficult to determine, whether higher or lower. However, the elimination of NDTIR from the NCTI calculation and the reduced section 250 deduction rates for both FDDEI and NCTI may impact companies that previously relied on FDII and GILTI deductions to lower their tax burden.
Their interaction with the so-called “Big Three” domestic business tax relief provisions introduces additional considerations for multinational enterprises (MNEs). The Big Three consists of:
- More favorable tax treatment of R&D expenses under section 174
- A more favorable limit to deducting business interest expense under section 163(j)
- Full expensing of qualified assets in the year they’re placed in service, known as 100% bonus depreciation
Section 174: R&D expenses
The OBBBA reverses a recent tightening of research cost recovery. Effective Jan. 1, 2025, taxpayers can immediately deduct all domestic R&D expenses rather than capitalizing and amortizing them over five years as was required under prior TCJA rules. Small businesses may even elect to apply this change retroactively to 2022, accelerating remaining amortization deductions.
Notably, no changes were made to the tax treatment of foreign R&D. Costs for research conducted outside the United States must still be capitalized and amortized over 15 years. However, the OBBBA amends the FDDEI rules so that R&D expenses are not allocated against DEI in computing FDDEI.
Under the pre-OBBBA framework, a portion of R&D costs could be allocated to foreign-derived income, reducing the FDII benefit. Now, all R&D is effectively treated as related to U.S. income for FDDEI purposes beginning after Dec. 31, 2025, maximizing the income that can qualify for the FDDEI deduction.
Likewise, for NCTI, domestic R&D expenses will not be apportioned to the NCTI foreign tax credit basket. In fact, under section 861-17, R&D expenditures are already excluded from apportionment to the GILTI (now NCTI) category.
In practice, this means a U.S. multinational can fully deduct its domestic research costs without reducing the portion of income benefiting from the FDDEI deduction or losing the capacity to credit CFC taxes under NCTI.